Stephens Issues Positive Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its target price increased by Stephens from $7.00 to $9.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an equal weight rating on the stock.

HCAT has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Evercore ISI lifted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Piper Sandler decreased their target price on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Royal Bank of Canada lifted their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Finally, Citigroup lifted their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $11.71.

Health Catalyst Stock Down 9.5 %

NASDAQ:HCAT traded down $0.80 during mid-day trading on Thursday, hitting $7.65. 637,468 shares of the company’s stock were exchanged, compared to its average volume of 562,503. Health Catalyst has a one year low of $5.42 and a one year high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business has a fifty day moving average price of $8.15 and a 200 day moving average price of $7.21. The company has a market cap of $465.50 million, a PE ratio of -6.08 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same period in the previous year, the firm earned ($0.22) EPS. The company’s revenue was up 3.5% on a year-over-year basis. Equities analysts predict that Health Catalyst will post -0.35 EPS for the current year.

Insider Buying and Selling

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the transaction, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently modified their holdings of HCAT. Quest Partners LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC raised its holdings in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after acquiring an additional 5,232 shares during the period. Quarry LP lifted its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Health Catalyst in the third quarter worth about $59,000. Finally, Perfromance Wealth Partners LLC bought a new position in shares of Health Catalyst in the second quarter worth about $64,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.